All Columns articles – Page 53
-
-
Opinion
Pactamycin
Labelling a molecule 'inaccessible to synthesis' is a red rag to a bull, says Paul Docherty
-
OpinionCompulsory licences: necessity or threat?
Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?
-
OpinionFlying: heavier or lighter than air?
Hydrogen balloons have fallen out of favour, except in chemistry demonstrations
-
Opinion
The name's (quadruple) bond?
Philip Ball discusses the contentious issue of C2 bonding. Dare we draw four lines?
-
Opinion
Flashback: 1993 – problems at Pittcon
Snow storms stranded people at Pittcon in 1993, making the conference memorable for the wrong reasons
-
OpinionBespoke or bodged
A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe
-
OpinionQuantum leaps of faith
The path to quantum mechanics becomes smoother if you take a different route, says Philip Ball
-
-
OpinionChemical bibliometrics
Andreas Barth suggests that regarding research from a molecular viewpoint reveals the big picture
-
-
OpinionOpening up and sharing
Openly sharing information and research is changing chemistry, says Jean-Claude Bradley. Be first, or be forgotten
-
Opinion
Pesticide bee buzz needs more evidence
Politicians should not rush to ban neonicotinoids until field trials have proved that they are wiping out bee colonies, argues Mark Peplow
-
OpinionAn artful solution to scientist shortfall
Joe Connor recalls a little known scheme to persuade arts students into science and asks what we might learn from it today
-
Opinion
From lab to leader
Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?
-
Opinion20 years ago: The rising tide
Committee of Women in Science and Technology is set up by the Office of Science and Technology